The historical rank and industry rank for Bajaj Healthcare's FCF Margin % or its related term are showing as below:
BOM:539872'
s FCF Margin % Range Over the Past 10 Years
Min: -17.93 Med: 1.82 Max: 13.11
Current: 2.41
During the past 13 years, the highest FCF Margin % of Bajaj Healthcare was 13.11%. The lowest was -17.93%. And the median was 1.82%.
BOM:539872's FCF Margin % is ranked worse than 50.31% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs BOM:539872: 2.41
Bajaj Healthcare FCF Margin % Related Terms
Bajaj Healthcare FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bajaj Healthcare's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bajaj Healthcare's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bajaj Healthcare FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bajaj Healthcare's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bajaj Healthcare's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bajaj Healthcare (BOM:539872) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bajaj Healthcare and its competitors. According to the industry distribution chart, Bajaj Healthcare ranks #483 out of 960 companies in the Drug Manufacturers industry, placing it in the top 50.3%.
Is Bajaj Healthcare's FCF Margin % too high?
Bajaj Healthcare's current FCF Margin % is 0.00%. Based on the distribution chart, Bajaj Healthcare ranks #483 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bajaj Healthcare has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bajaj Healthcare's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bajaj Healthcare ranks #483 out of 960 companies for FCF Margin %. This places Bajaj Healthcare in the lower half of its industry. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bajaj Healthcare and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bajaj Healthcare's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bajaj Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Bajaj Healthcare (BOM:539872) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹404.46, compared to a current price of ₹344.75 — trading 14.8% below its estimated fair value. The current FCF Margin % is 0.00%. Bajaj Healthcare's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bajaj Healthcare (BOM:539872), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bajaj Healthcare (BOM:539872) Overvalued in 2026?
Based on GuruFocus' analysis, Bajaj Healthcare stock appears to be undervalued.
The current stock price of ₹344.75 is trading 14.8% below its estimated GF Value™ of ₹404.46.
GuruFocus considers Bajaj Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:539872:
FCF Margin %: 0.00%
GF Value™: ₹404.46 vs. price of ₹344.75 (14.8% below fair value)
No single metric tells the full story. See the BOM:539872 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bajaj Healthcare Ltd is an India-based pharmaceutical company that manufactures Active Pharmaceutical Ingredients (APIs), Intermediates, Finished Dosage Forms, and Nutraceuticals. Its products include Intermediates, API, Formulation, and Impurities. The company derives a majority of its revenue from India.
62GF Score
Get the complete analysis for BOM:539872
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539872 has been successfully added to your 
